株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

1型糖尿病:疫学的予測

Type 1 Diabetes: Epidemiology Forecast to 2026

発行 GlobalData 商品コード 876685
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.60円で換算しております。
Back to Top
1型糖尿病:疫学的予測 Type 1 Diabetes: Epidemiology Forecast to 2026
出版日: 2019年04月30日 ページ情報: 英文 29 Pages
概要

当レポートでは、世界の主要8ヶ国 (8MM:米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、日本) における1型糖尿病の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の総数と傾向 (年齢層別・男女別傾向)、今後10年間の動向見通しなどを調査しております。

第1章 目次

第2章 1型糖尿病:エグゼクティブ・サマリー

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
  • 1型糖尿病の疫学的予測 (今後11年間分)
    • 1型糖尿病の受診済み有病者数 (総数)
    • 1型糖尿病の受診済み有病者数:年齢層別
    • 1型糖尿病の受診済み有病者数:男女別
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: Risk Factors and Comorbidities for Type 1 Diabetes

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2016 and 2026
  • Figure 2: 8MM, Diagnosed Prevalence (%) of Type 1 Diabetes, Men, All Ages, 2006-2026
  • Figure 3: 8MM, Diagnosed Prevalence (%) of Type 1 Diabetes, Women, All Ages, 2006-2026
  • Figure 4: 8MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Type 1 Diabetes
  • Figure 5: 8MM, Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, Both Sexes, N, 2016
  • Figure 6: 8MM, Age-Specific Diagnosed Prevalent Cases of Type 1 Diabetes, Both Sexes, N, 2016
  • Figure 7: 8MM, Sex-Specific Diagnosed Prevalent Cases of Type 1 Diabetes, All Ages, N, 2016
目次
Product Code: GDHCER202-19

Type 1 diabetes, formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. Type 1 diabetes accounts for about 5-10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin, a hormone that regulates blood sugar. If the condition is left untreated, blood sugar levels accumulate. In addition to the pancreas, high levels of blood sugar can damage other major organs, such as the heart, blood vessels, nerves, eyes, and kidneys. Such damage can be life threatening. Furthermore, research suggests that the incidence of type 1 diabetes is increasing globally, which may lead to an increased burden on healthcare resources (Holt, 2004; World Health Organization, 2013; Mayo Clinic, 2017).

To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of type 1 diabetes in the 8MM.

In the 8MM, the diagnosed prevalent cases of type 1 diabetes will increase from 3,396,254 cases in 2016 to 4,725,990 cases in 2026, at an Annual Growth Rate (AGR) of 3.92% per year. Among the 8MM, the US had the highest number of diagnosed prevalent cases of type 1 diabetes in 2016 and 2026, at 1,564,973 cases and 2,274,873 cases, respectively. Canada had the lowest number of prevalent cases of type 1 diabetes in 2016 and 2026, at 163,113 cases and 254,166 cases, respectively. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of type 1 diabetes in the 8MM to environmental factors (seasonal variation) coupled with genetic factors, such as a family history of type 1 diabetes. However, further research is necessary to clearly understand the epidemiological factors responsible for the growth in the prevalent cases of type 1 diabetes (Onkamo et al., 1999).

Scope

  • The Type 1 Diabetes Epidemiology Report provides an overview of the risk factors and global trends of type 1 diabetes in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of type 1 diabetes segmented by age (ages under 20 years, 20-29 years, 30-44 years, 45-59 years, 60-74 years, and 75 years and older) and sex in these markets. To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of type 1 diabetes in the 8MM.
  • The type 1 diabetes epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Type 1 Diabetes Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
  • Quantify patient populations in the global type 1 diabetes market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for type 1 diabetes therapeutics in each of the markets covered.

Table of Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Type 1 Diabetes: Executive Summary
    • 2.1 Related Reports
    • 2.2 Upcoming Reports
  • 3 Epidemiology
    • 3.1 Disease Background
    • 3.2 Risk Factors and Comorbidities
    • 3.3 Global and Historical Trends
    • 3.4 Forecast Methodology
      • 3.4.1 Sources
      • 3.4.2 Forecast Assumptions and Methods
    • 3.5 Epidemiological Forecast for Type 1 Diabetes (2016-2026)
      • 3.5.1 Diagnosed Prevalent Cases of Type 1 Diabetes
      • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Type 1 Diabetes
      • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Type 1 Diabetes
    • 3.6 Discussion
      • 3.6.1 Epidemiological Forecast Insight
      • 3.6.2 Limitations of the Analysis
      • 3.6.3 Strengths of the Analysis
  • 4 Appendix
    • 4.1 Bibliography
    • 4.2 Abbreviations
    • 4.3 About the Authors
      • 4.3.1 Epidemiologist
      • 4.3.2 Reviewers
      • 4.3.3 Global Director of Therapy Analysis and Epidemiology
      • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
    • 4.4 About GlobalData
    • 4.5 Contact Us
    • 4.6 Disclaimer
Back to Top